Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Sports medicine specialist Andrew Garnham said on Tuesday he had asked ASADA in February 2013 about the status of AOD-9604 in his capacity as a member of the AFL's Anti-Doping Tribunal
Frequently asked questions Can I inject AOD 9604 and tirzepatide at the same site
Absolute Contraindications BPC-157 is not recommended for patients with: Active cancer (any type) theoretical concern regarding angiogenesis promotion Pregnancy or breastfeeding insufficient safety data Known hypersensitivity to any component of the formulation Relative Contraindications (Require Individualized Assessment) History of cancer after completion of treatment, a waiting period and oncology clearance may be appropriate Autoimmune disease especially if active or requiring immunosuppressive therapy Anticoagulant use injection site bleeding risk, though minimal with proper technique Severe renal or hepatic impairment dosing adjustments may be needed Monitoring and Follow-Up Patients on BPC-157 protocols are monitored through: Baseline and follow-up labs including inflammatory markers (CRP, ESR), complete blood count, and metabolic panel Clinical assessments pain scores, range of motion, functional outcomes at 2-week, 4-week, and 8-week intervals Imaging when indicated repeat ultrasound or MRI for musculoskeletal conditions to document structural healing The Patient Journey: What to Expect For patients considering peptide therapy, understanding the timeline of response helps set realistic expectations
Safety and tolerability
The formula should be stable, ideally in an opaque, air-tight bottle, and include ingredients that support skin health like hydrators and antioxidants, adds Dr
